Hims & Hers Health Shares Tumble as its Weight-Loss Treatments Face Tough Environment
Hims is pivoting after drugmaker Novo Nordisk on Friday said the Food and Drug Administration has determined that the shortage of Wegovy and Ozempic has been resolved. Compounding its challenges in the space is a decision by drugmaker Eli Lilly on Tuesday to cut prices of Zepbound, another weight-loss drug.
Hims & Hers Health, Inc. (NYSE:HIMS) announced the acquisition of a California-based peptide facility to enhance its domestic ...
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...
Hims & Hers Health reports its fourth-quarter results after Monday's closing bell. Here's a look at the key figures from the ...
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Hims & Hers Health, Inc. showcases strong growth with diverse revenue streams. Discover why its stock dip offers a unique opportunity. Learn more on HIMS stock here.
Shares of Hims & Hers Health Inc (NYSE: HIMS) are flying higher on Wednesday. The company's stock gained 21.7% as of 2:00 p.m ...
Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback